Skip to main content
Fig. 2 | BMC Endocrine Disorders

Fig. 2

From: Recombinant growth hormone therapy in children with Turner Syndrome in Korea: a phase III Randomized Trial

Fig. 2

Annualized HV at baseline, 13, 26, 39, and 52-week (cm/year) and change in annualized HV from baseline at 52-week. a: Annualized HV at baseline, 13, 26, 39 and 52-week; b: Change in annualized HV from baseline at 52-week. HV: height velocity; SE: Standard Error; * LS mean difference for between-treatment groups using ANCOVA model with treatment group as a factor and CA at baseline as a covariate

Back to article page